Archived Newsletters
-
03.11.24 -- Overcoming Advanced Therapy Development Hurdles
3/11/2024
03/11/24 Outsourced Pharma Newsletter
-
03.11.24 -- When In The Product's Life Cycle Does Continuous Manufacturing Make Sense?
3/11/2024
03/11/24 Outsourced Pharma Newsletter
-
03.08.24 -- New Episodes: Yescarta's Reduced Median Turnaround Time, Inhalable mRNA and more!
3/8/2024
03/08/24 Outsourced Pharma Newsletter
-
03.08.24 -- Indo-U.S. Collaboration Can Accelerate Drug Discovery – Here's How
3/8/2024
03/08/24 Outsourced Pharma Newsletter
-
03.07.24 -- Is WuXi Apptec An Enemy Of The State?
3/7/2024
03/07/24 Outsourced Pharma Newsletter
-
03.06.24 -- A New Approach To Allogeneic Cell Therapy Process Development
3/6/2024
03/06/24 Outsourced Pharma Newsletter
-
03.06.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
3/6/2024
03/06/24 Outsourced Pharma Newsletter
-
03.05.24 -- New CRISPR Delivery Methods, Next-Generation Plasmid Vectors, And RNP Analytics For Reduced Off-Target Effects
3/5/2024
03/05/24 Outsourced Pharma Newsletter
-
03.05.24 -- What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry?
3/5/2024
03/05/24 Outsourced Pharma Newsletter
-
03.04.24 -- A Patient- And Planet-Centric Approach To Enhancing Medicines In Development
3/4/2024
03/04/24 Outsourced Pharma Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more